Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

IGF2 Mutations: Report of Five Cases, Review of the Literature, and Comparison with H19/IGF2:IG-DMR Epimutations.

Masunaga Y, Inoue T, Yamoto K, Fujisawa Y, Sato Y, Kawashima-Sonoyama Y, Morisada N, Iijima K, Ohata Y, Namba N, Suzumura H, Kuribayashi R, Yamaguchi Y, Yoshihashi H, Fukami M, Saitsu H, Kagami M, Ogata T.

J Clin Endocrinol Metab. 2019 Sep 23. pii: dgz034. doi: 10.1210/clinem/dgz034. [Epub ahead of print]

PMID:
31544945
2.

MYRF haploinsufficiency causes 46,XY and 46,XX disorders of sex development: bioinformatics consideration.

Hamanaka K, Takata A, Uchiyama Y, Miyatake S, Miyake N, Mitsuhashi S, Iwama K, Fujita A, Imagawa E, Alkanaq AN, Koshimizu E, Azuma Y, Nakashima M, Mizuguchi T, Saitsu H, Wada Y, Minami S, Katoh-Fukui Y, Masunaga Y, Fukami M, Hasegawa T, Ogata T, Matsumoto N.

Hum Mol Genet. 2019 Jul 15;28(14):2319-2329. doi: 10.1093/hmg/ddz066.

PMID:
30985895
3.

Germline-Derived Gain-of-Function Variants of Gsα-Coding GNAS Gene Identified in Nephrogenic Syndrome of Inappropriate Antidiuresis.

Miyado M, Fukami M, Takada S, Terao M, Nakabayashi K, Hata K, Matsubara Y, Tanaka Y, Sasaki G, Nagasaki K, Shiina M, Ogata K, Masunaga Y, Saitsu H, Ogata T.

J Am Soc Nephrol. 2019 May;30(5):877-889. doi: 10.1681/ASN.2018121268. Epub 2019 Apr 8.

PMID:
30962325
4.

Community perspectives on treating asymptomatic infections for malaria elimination in The Gambia.

Jaiteh F, Masunaga Y, Okebe J, D'Alessandro U, Balen J, Bradley J, Gryseels C, Ribera JM, Grietens KP.

Malar J. 2019 Feb 18;18(1):39. doi: 10.1186/s12936-019-2672-7.

5.

Reactive community-based self-administered treatment against residual malaria transmission: study protocol for a randomized controlled trial.

Okebe J, Ribera JM, Balen J, Jaiteh F, Masunaga Y, Nwakanma D, Bradley J, Yeung S, Peeters Grietens K, D'Alessandro U.

Trials. 2018 Feb 20;19(1):126. doi: 10.1186/s13063-018-2506-x.

6.

Human cytochrome P450 1A1 is a novel target gene of liver X receptor α.

Shibahara N, Masunaga Y, Iwano S, Yamazaki H, Kiyotani K, Kamataki T.

Drug Metab Pharmacokinet. 2011;26(5):451-7. Epub 2011 Jun 7.

7.

Influence of clinical and genetic factors on warfarin dose requirements among Japanese patients.

Ohno M, Yamamoto A, Ono A, Miura G, Funamoto M, Takemoto Y, Otsu K, Kouno Y, Tanabe T, Masunaga Y, Nonen S, Fujio Y, Azuma J.

Eur J Clin Pharmacol. 2009 Nov;65(11):1097-103. doi: 10.1007/s00228-009-0685-9. Epub 2009 Jul 7.

PMID:
19582440
8.

Expression profiles of cytokines and chemokines in murine MDR1a-/- colitis.

Masunaga Y, Noto T, Suzuki K, Takahashi K, Shimizu Y, Morokata T.

Inflamm Res. 2007 Nov;56(11):439-46. doi: 10.1007/s00011-007-6078-6.

PMID:
18224285
9.

Meta-analysis of risk of malignancy with immunosuppressive drugs in inflammatory bowel disease.

Masunaga Y, Ohno K, Ogawa R, Hashiguchi M, Echizen H, Ogata H.

Ann Pharmacother. 2007 Jan;41(1):21-8. Epub 2007 Jan 2.

PMID:
17200426
10.

A novel, selective, and orally available antagonist for CC chemokine receptor 3.

Morokata T, Suzuki K, Masunaga Y, Taguchi K, Morihira K, Sato I, Fujii M, Takizawa S, Torii Y, Yamamoto N, Kaneko M, Yamada T, Takahashi K, Shimizu Y.

J Pharmacol Exp Ther. 2006 Apr;317(1):244-50. Epub 2005 Dec 9.

PMID:
16339911
11.

Cytokine and chemokine expression in cigarette smoke-induced lung injury in guinea pigs.

Kubo S, Kobayashi M, Masunaga Y, Ishii H, Hirano Y, Takahashi K, Shimizu Y.

Eur Respir J. 2005 Dec;26(6):993-1001.

12.

A case of encapsulating peritoneal sclerosis at the clinical early stage with high concentration of matrix metalloproteinase-2 in peritoneal effluent.

Masunaga Y, Hirahara I, Shimano Y, Kurosu M, Iimura O, Miyata Y, Amemiya M, Homma S, Kusano E, Asano Y.

Clin Exp Nephrol. 2005 Mar;9(1):85-9.

PMID:
15830280
14.

[A systematic review of the clinical effectiveness of azathioprine in patients with ulcerative colitis].

Ohno K, Masunaga Y, Ogawa R, Hashiguchi M, Ogata H.

Yakugaku Zasshi. 2004 Aug;124(8):555-60. Review. Japanese.

15.

Ascites from patients with encapsulating peritoneal sclerosis augments NIH/3T3 fibroblast proliferation.

Masunaga Y, Muto S, Asakura S, Akimoto T, Homma S, Kusano E, Asano Y.

Ther Apher Dial. 2003 Oct;7(5):486-93.

PMID:
14708905
16.

Multimeric vitronectin in ascites is involved in fibroblast spreading of EPS in patients on CAPD therapy.

Masunaga Y, Asakura S, Muto S, Ando Y, Homma S, Kusano E, Matsuda M, Asano Y.

Clin Exp Nephrol. 2003 Jun;7(2):150-6.

PMID:
14586734
17.

Dendritic cells transduced with gp100 gene by RGD fiber-mutant adenovirus vectors are highly efficacious in generating anti-B16BL6 melanoma immunity in mice.

Okada N, Masunaga Y, Okada Y, Mizuguchi H, Iiyama S, Mori N, Sasaki A, Nakagawa S, Mayumi T, Hayakawa T, Fujita T, Yamamoto A.

Gene Ther. 2003 Oct;10(22):1891-902.

PMID:
14502218
18.

Combined treatment with nafamostat mesilate and aspirin prevents heparin-induced thrombocytopenia in a hemodialysis patient.

Takahashi H, Muto S, Nakazawa E, Yanagiba S, Masunaga Y, Miyata Y, Tamba K, Kusano E, Matsuo M, Matsuo T, Asano Y.

Clin Nephrol. 2003 Jun;59(6):458-62.

PMID:
12834179
19.

Gene transduction efficiency and maturation status in mouse bone marrow-derived dendritic cells infected with conventional or RGD fiber-mutant adenovirus vectors.

Okada N, Masunaga Y, Okada Y, Iiyama S, Mori N, Tsuda T, Matsubara A, Mizuguchi H, Hayakawa T, Fujita T, Yamamoto A.

Cancer Gene Ther. 2003 May;10(5):421-31.

PMID:
12719712
20.

Changes in peritoneal coagulation and fibrinolysis after discontinuation of chronic peritoneal dialysis.

Homma S, Masunaga Y, Kurosu M, Inoue M, Sakurai T, Asano Y.

Perit Dial Int. 2002 Mar-Apr;22(2):178-83.

PMID:
11990401
21.

Rapid and persistent reduction of proteinuria following plasma exchange in a case of steroid-resistant focal segmental glomerulosclerosis.

Ishii E, Ando Y, Tamba K, Masunaga Y, Kusano E, Asano Y.

Ther Apher. 2002 Apr;6(2):174-7. Review.

PMID:
11982961
22.

Identification of multiple isolated lymphoid follicles on the antimesenteric wall of the mouse small intestine.

Hamada H, Hiroi T, Nishiyama Y, Takahashi H, Masunaga Y, Hachimura S, Kaminogawa S, Takahashi-Iwanaga H, Iwanaga T, Kiyono H, Yamamoto H, Ishikawa H.

J Immunol. 2002 Jan 1;168(1):57-64.

23.

Efficient antigen gene transduction using Arg-Gly-Asp fiber-mutant adenovirus vectors can potentiate antitumor vaccine efficacy and maturation of murine dendritic cells.

Okada N, Saito T, Masunaga Y, Tsukada Y, Nakagawa S, Mizuguchi H, Mori K, Okada Y, Fujita T, Hayakawa T, Mayumi T, Yamamoto A.

Cancer Res. 2001 Nov 1;61(21):7913-9.

24.

Effects of lipofectin-antigen complexes on major histocompatibility complex class I-restricted antigen presentation pathway in murine dendritic cells and on dendritic cell maturation.

Okada N, Saito T, Mori K, Masunaga Y, Fujii Y, Fujita J, Fujimoto K, Nakanishi T, Tanaka K, Nakagawa S, Mayumi T, Fujita T, Yamamoto A.

Biochim Biophys Acta. 2001 Aug 15;1527(3):97-101.

PMID:
11479025
25.

Quantitative detection of a DNA ligase reaction on a quartz-crystal microbalance.

Okahata Y, Masunaga Y, Matsuno H, Furusawa H.

Nucleic Acids Symp Ser. 1999;(42):147-8.

PMID:
10780422
26.

Human recombinant erythropoietin inhibits interleukin-1beta-stimulated nitric oxide and cyclic guanosine monophosphate production in cultured rat vascular smooth-muscle cells.

Kusano E, Akimoto T, Inoue M, Masunaga Y, Umino T, Ono S, Ando Y, Homma S, Muto S, Komatsu N, Asano Y.

Nephrol Dial Transplant. 1999 Mar;14(3):597-603.

PMID:
10193805
27.

Diameter of the inferior vena cava as an index of dry weight in patients undergoing CAPD.

Sakurai T, Ando Y, Masunaga Y, Kusano E, Asano Y.

Perit Dial Int. 1996 Mar-Apr;16(2):183-5. No abstract available.

PMID:
9147557
28.

Effect of the angiotensin converting enzyme inhibitor, captopril, on proteinuria in chronic glomerular disease.

Masunaga Y, Tabei K, Takeda S, Ando Y, Kusano E, Asano Y.

Nihon Jinzo Gakkai Shi. 1993 Aug;35(8):961-6.

PMID:
8255007
29.

[Improved nursing of patients receiving cisplatin: keypoints in easing nausea and vomiting and guidance in the diet].

Takahashi S, Sawamura N, Funamoto H, Umehara H, Masunaga Y, Yokoyama S.

Kangogaku Zasshi. 1985 Feb;49(2):185-8. Japanese. No abstract available.

PMID:
3845151
30.

[Significance of the bioclean room during the treatment of lung cancer].

Sawamura N, Akagi E, Naraoka I, Masunaga Y, Yokoyama S, Saijo N.

Gan To Kagaku Ryoho. 1984 Feb;11(2):253-9. Japanese.

PMID:
6696461
31.

[Aspects of semi-clean room utilization for lung cancer patients under chemotherapy, and nursing care].

Akagi E, Sawamura N, Naraoka I, Masunaga Y, Yokoyama S.

Kango Gijutsu. 1984 Feb;30(3):395-8. Japanese. No abstract available.

PMID:
6560041
32.

[Current trends nuclear medicine].

Yasokuchi H, Uno K, Taniguchi K, Murakami Y, Masunaga Y.

Kango Gijutsu. 1977 Nov;23(15):9-15. Japanese. No abstract available.

PMID:
243578
33.

[A case of diffuse superior mesenteric arteriovenous malformation considered congenital in origin (author's transl)].

Matsumoto K, Murakami Y, Uno K, Masunaga Y, Yasukochi H.

Nihon Igaku Hoshasen Gakkai Zasshi. 1977 Sep;37(9):848-55. Japanese. No abstract available.

PMID:
917754

Supplemental Content

Loading ...
Support Center